{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:48:34Z","timestamp":1791643714642,"version":"4.3.4"},"reference-count":62,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.rdc.2017.06.007","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T20:16:17Z","timestamp":1504210577000},"page":"579-591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Neuromyelitis Optica"],"prefix":"10.1016","volume":"43","author":[{"given":"Sarah L.","family":"Patterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Goglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rdc.2017.06.007_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jocn.2012.12.022","article-title":"Neuromyelitis optica: concept, immunology and treatment","volume":"21","author":"Uzawa","year":"2014","journal-title":"J\u00a0Clin Neurosci"},{"issue":"1","key":"10.1016\/j.rdc.2017.06.007_bib2","first-page":"35","article-title":"An epidemiological study of neuromyelitis optica in Cuba","volume":"256","author":"Cabrera-Gomez","year":"2009","journal-title":"J\u00a0Neurol"},{"issue":"18","key":"10.1016\/j.rdc.2017.06.007_bib3","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.0b013e3182190f74","article-title":"A\u00a0population-based study of neuromyelitis optica in Caucasians","volume":"76","author":"Asgari","year":"2011","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.rdc.2017.06.007_bib4","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.rdc.2017.06.007_bib5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.rdc.2017.06.007_bib6","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur J Neurol"},{"issue":"9","key":"10.1016\/j.rdc.2017.06.007_bib7","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.rdc.2017.06.007_bib8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.nic.2008.09.002","article-title":"The clinical epidemiology of multiple sclerosis","volume":"18","author":"Confavreux","year":"2008","journal-title":"Neuroimaging Clin N Am"},{"issue":"24","key":"10.1016\/j.rdc.2017.06.007_bib9","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.rdc.2017.06.007_bib10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.rdc.2017.06.007_bib11","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-012-0986-4","article-title":"Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss","volume":"123","author":"Ratelade","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"Pt 2","key":"10.1016\/j.rdc.2017.06.007_bib12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"issue":"Pt 5","key":"10.1016\/j.rdc.2017.06.007_bib13","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"issue":"Pt 11","key":"10.1016\/j.rdc.2017.06.007_bib14","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.rdc.2017.06.007_bib15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","journal-title":"J\u00a0Neuroinflammation"},{"issue":"1\u20132","key":"10.1016\/j.rdc.2017.06.007_bib16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","journal-title":"J\u00a0Neurol Sci"},{"issue":"9","key":"10.1016\/j.rdc.2017.06.007_bib17","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"15","key":"10.1016\/j.rdc.2017.06.007_bib18","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1212\/WNL.0b013e31824f8069","article-title":"Clinical spectrum of CNS aquaporin-4 autoimmunity","volume":"78","author":"Kim","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.rdc.2017.06.007_bib19","first-page":"47","article-title":"Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica","volume":"251","author":"Ghezzi","year":"2004","journal-title":"J\u00a0Neurol"},{"issue":"5","key":"10.1016\/j.rdc.2017.06.007_bib20","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.rdc.2017.06.007_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"4\u20135","key":"10.1016\/j.rdc.2017.06.007_bib22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.autrev.2014.01.034","article-title":"Diagnosis and classification of neuromyelitis optica (Devic's syndrome)","volume":"13","author":"Drori","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.rdc.2017.06.007_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ncl.2012.09.008","article-title":"Transverse myelitis","volume":"31","author":"Beh","year":"2013","journal-title":"Neurol Clin"},{"issue":"2","key":"10.1016\/j.rdc.2017.06.007_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0032-1322586","article-title":"Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies","volume":"32","author":"West","year":"2012","journal-title":"Semin Neurol"},{"issue":"88","key":"10.1016\/j.rdc.2017.06.007_bib25","first-page":"167","article-title":"Transverse myelitis\u2013a review of the presentation, diagnosis, and initial management","volume":"16","author":"West","year":"2013","journal-title":"Discov Med"},{"issue":"4","key":"10.1016\/j.rdc.2017.06.007_bib26","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1212\/WNL.59.4.499","article-title":"Proposed diagnostic criteria and nosology of acute transverse myelitis","volume":"59","year":"2002","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.rdc.2017.06.007_bib27","first-page":"163","article-title":"Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study","volume":"255","author":"Nakamura","year":"2008","journal-title":"J\u00a0Neurol"},{"issue":"10","key":"10.1016\/j.rdc.2017.06.007_bib28","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1007\/s00330-009-1425-3","article-title":"Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study","volume":"19","author":"Krampla","year":"2009","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.rdc.2017.06.007_bib29","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/BF00451760","article-title":"STIR sequences in NMR imaging of the optic nerve","volume":"29","author":"Johnson","year":"1987","journal-title":"Neuroradiology"},{"issue":"Pt 4","key":"10.1016\/j.rdc.2017.06.007_bib30","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/brain\/awf087","article-title":"Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance","volume":"125","author":"Kupersmith","year":"2002","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.rdc.2017.06.007_bib31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/1352458513507822","article-title":"Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients","volume":"20","author":"Kremer","year":"2014","journal-title":"Mult Scler"},{"issue":"9451","key":"10.1016\/j.rdc.2017.06.007_bib32","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A\u00a0serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.rdc.2017.06.007_bib33","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1212\/WNL.0b013e318296e917","article-title":"Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity","volume":"80","author":"Marignier","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.rdc.2017.06.007_bib34","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1212\/NXI.0000000000000011","article-title":"AQP4 autoantibody assay performance in clinical laboratory service","volume":"1","author":"Fryer","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"15","key":"10.1016\/j.rdc.2017.06.007_bib35","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.rdc.2017.06.007_bib36","first-page":"1","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.rdc.2017.06.007_bib37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.rdc.2017.06.007_bib38","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.rdc.2017.06.007_bib39","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/1352458506071174","article-title":"Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler"},{"key":"10.1016\/j.rdc.2017.06.007_bib40","article-title":"Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders","author":"Montcuquet","year":"2016","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.rdc.2017.06.007_bib41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.rdc.2017.06.007_bib42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/1756285611398939","article-title":"Current and future treatment approaches for neuromyelitis optica","volume":"4","author":"Collongues","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"issue":"7","key":"10.1016\/j.rdc.2017.06.007_bib43","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1177\/1352458515602337","article-title":"Efficacy of rituximab in refractory neuromyelitis optica","volume":"22","author":"Collongues","year":"2016","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.rdc.2017.06.007_bib44","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/1756285616632653","article-title":"An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica","volume":"9","author":"Collongues","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"10.1016\/j.rdc.2017.06.007_bib45","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A\u00a05-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.rdc.2017.06.007_bib46","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.rdc.2017.06.007_bib47","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archneurol.2010.322","article-title":"Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.rdc.2017.06.007_bib48","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jnnp-2012-303121","article-title":"Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study","volume":"84","author":"Cabre","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.rdc.2017.06.007_bib49","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.rdc.2017.06.007_bib50","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3109\/s10165-012-0715-9","article-title":"Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab","volume":"23","author":"Araki","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"15","key":"10.1016\/j.rdc.2017.06.007_bib51","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.rdc.2017.06.007_bib52","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.rdc.2017.06.007_bib53","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2013.668","article-title":"Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses","volume":"70","author":"Kieseier","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.rdc.2017.06.007_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-202939","article-title":"Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab","volume":"2014","author":"Lauenstein","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"15","key":"10.1016\/j.rdc.2017.06.007_bib55","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1212\/WNL.0000000000000322","article-title":"Devic disease: translational medicine at work","volume":"82","author":"Rose-John","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.rdc.2017.06.007_bib56","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.rdc.2017.06.007_bib57","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann Neurol"},{"issue":"10","key":"10.1016\/j.rdc.2017.06.007_bib58","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/jnnp.2007.143529","article-title":"Relapsing neuromyelitis optica: long term history and clinical predictors of death","volume":"80","author":"Cabre","year":"2009","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.rdc.2017.06.007_bib59","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","article-title":"Neuromyelitis optica: clinical predictors of a relapsing course and survival","volume":"60","author":"Wingerchuk","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.rdc.2017.06.007_bib60","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1001\/archophthalmol.2007.26","article-title":"Clinical course of optic neuritis in patients with relapsing neuromyelitis optica","volume":"126","author":"Papais-Alvarenga","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.rdc.2017.06.007_bib61","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/B978-0-444-52001-2.00027-3","article-title":"Acute inflammatory myelopathies","volume":"122","author":"Cree","year":"2014","journal-title":"Handb Clin Neurol"},{"issue":"3","key":"10.1016\/j.rdc.2017.06.007_bib62","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1352458511406165","article-title":"The differential diagnosis of longitudinally extensive transverse myelitis","volume":"18","author":"Kitley","year":"2012","journal-title":"Mult Scler"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X17300510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X17300510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:16:29Z","timestamp":1760181389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X17300510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0889857X17300510"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2017.06.007","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuromyelitis Optica","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2017.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}